MTOR and hepatocellular carcinoma: Collectively, our data indicated that overexpression of CDCA2 facilitated the growth and mobility of HCC cells partly through controlling AKT–mTOR pathway, providing evidence for CDCA2 as a biomarker and a potential target molecule for the treatment of HCC.